 |
|
Advances in Drug Therapy for Peptic Ulcer Disease
Theodore N. Pappas, MD;
Sean J. Mulvihill, MD;
Yositi Goto, PhD;
Haile T. Debas, MD
Arch Surg. 1987;122(4):447-450.
Abstract
• Recently, three new drug types have emerged to treat peptic ulceration. We compared the mechanism of action of omeprazole and somatostatin-14, both inhibitors of gastric acid, with that of tetraprenylacetone, a drug thought to be cytoprotective in the upper gut. Omeprazole and somatostatin-14 caused potent inhibition of meal-stimulated acid secretion in the dog (92% ± 6% and 97% ±1%, respectively). On the other hand, tetraprenylacetone had no significant inhibitory effect on acid secretion (4%±17%). In separate studies, tetraprenylacetone was shown to be a stimulant of gastric bicarbonate secretion in the rabbit, increasing bicarbonate secretion from a basal level of 0 to 86±28 pmol/2 h. Tetraprenylacetone was also found to be a strong stimulant of canine pancreatic bicarbonate secretion. The ability of tetraprenylacetone to stimulate endogenous bicarbonate secretion may explain its ability to heal ulcers both experimentally and clinically.
(Arch Surg 1987;122:447-450)
Author Affiliations
From the Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston (Dr Pappas); the Department of Surgery, UCLA Medical Center (Dr Mulvihill); and the Department of Surgery, University of Washington Medical Center, Seattle (Drs Goto and Debas).
Footnotes
Accepted for publication Dec 22, 1986.
Read before the 67th Annual Meeting of the New England Surgical Society, Dixville Notch, NH, Sept 27, 1986.
Reprints not available.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Geranylgeranylacetone Protects Membranes against Nonsteroidal Anti-Inflammatory Drugs
Ushijima et al.
Mol. Pharmacol. 2005;68:1156-1161.
ABSTRACT
| FULL TEXT
|
